|
Delayed
Nasdaq Stockholm
23:29:33 16/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1,593.00 SEK | -0.06% |
|
+4.87% | -6.49% |
| 09:55pm | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 04:47pm | Daiichi and AstraZeneca cancer drugs secure further approvals in Japan | AN |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 253,421 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -11.95% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 272,983 | 265,203 | 256,056 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -12.28% | -2.85% | -3.45% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.9x | 18.2x | 15.8x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.69x | 4.17x | 3.54x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.2x | 1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.01x | 3.79x | 3.55x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.31x | 3.97x | 3.59x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.3x | 10.9x | 9.58x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13x | 11.4x | 10x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.5x | 20.4x | 17.5x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.51% | 4.91% | 5.71% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.334 | 3.555 | 3.653 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.04% | 2.18% | 2.24% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.811 | 8.956 | 10.35 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.7% | 39.7% | 35.3% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,276 | 66,881 | 71,311 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,144 | 24,286 | 26,741 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,064 | 23,220 | 25,510 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,071 | 13,803 | 15,828 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,562 | 11,781 | 2,635 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 163.39 | 163.39 | 163.39 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/2/22 | 9/2/23 | 8/2/24 | 6/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.3x | 11.75x | 23.82x | 0.61% | 1,013B | |
| 29.72x | 6.61x | 18.51x | 2.01% | 644B | |
| 33.26x | 7.79x | 16.1x | 2.61% | 465B | |
| 19.53x | 4.77x | 11.83x | 2.78% | 352B | |
| 19.64x | 5.13x | 12.73x | 3.13% | 264B | |
| 20.94x | 4.32x | 12.33x | 2.04% | 253B | |
| 23.76x | 6.28x | 11.19x | 2.69% | 203B | |
| 12.28x | 4.47x | 9.35x | 4.09% | 188B | |
| -44.25x | 6.45x | 25.21x | 2.25% | 181B | |
| Average | 16.35x | 6.40x | 15.67x | 2.47% | 395.97B | |
| Weighted average by Cap. | 23.51x | 7.63x | 17.62x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
